PD1 gene polymorphism is associated with a poor prognosis in hepatocellular carcinoma following liver resection, cohort study.
PD1 gene polymorphism is associated with a poor prognosis in hepatocellular carcinoma following liver resection, cohort study.
复制标题
队列研究显示，PD1 基因多态性与肝切除术后肝细胞癌的不良预后相关。
DOI：
10.1016/j.ijsu.2020.05.007
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Ohdan H.
中科院分区：
文献类型：
--
作者：
Yamamoto M;Kobayashi T;Mashima H;Miki D;Kuroda S;Hamaoka M;Aikata H;Chayama K;Ohdan H.
本研究旨在探讨程序性细胞死亡蛋白(PD)-1的单核苷酸多态性（SNP）是否与肝细胞癌（HCC）患者术后预后有关。免疫检查点蛋白PD-1是T细胞反应的重要抑制剂。据报道，PD-1 -606 G/A启动子区域的SNP导致与癌症风险相关的PD-1的高激活和表达。材料和方法我们分析了2010年至2015年间行肝切除术的321例HCC患者。采用聚合酶链反应分析PD-1 SNP，分析HCC患者手术治疗后的预后。结果PD-1 SNP状态分别为AA 90（28.1%）、GA 163（50.8%）、GG 68（21.2%）。基线参数在三组间无统计学差异。GG基因型患者的总生存期（OS）显著低于其他基因型患者（P = 0.031）。GG基因型是OS的独立危险因素（P = 0.009; HR 2.201）。GG基因型与其他基因型在无复发生存率上无显著差异。GG基因型患者肝外复发率显著高于其他基因型患者（P = 0.036）。GG基因型是EHR的独立危险因素（P = 0.008; HR 2.037）。结论PD-1 SNP GG基因型与HCC患者生存差和EHR升高相关。此外，GG基因型是OS和EHR的独立预测因素。
BackgroundThis study examined whether single nucleotide polymorphism (SNP) in programmed cell death protein (PD)-1 is related to the postoperative prognosis of patients with hepatocellular carcinoma (HCC). The immune checkpoint protein PD-1 is an important inhibitor of T cell responses. SNP in the promoter region of PD-1 -606 G/A has been reported to result in high activation and expression of PD-1 associated with cancer risk.Materials and methodsWe analyzed 321 patients with HCC who underwent hepatectomy between 2010 and 2015. PD-1 SNP was analyzed by polymerase chain reaction, and the prognosis after surgical treatment of patients with HCC was analyzed.ResultsThe PD-1 SNP statuses were as follows: 90 AA (28.1%), 163 GA (50.8%), 68 GG (21.2%). The baseline parameters did not statistically differ between the three groups. The overall survival (OS) of patients with the GG genotype was significantly lower than that of those with the other genotypes (P = 0.031). The GG genotype was an independent risk factor for OS (P = 0.009; HR 2.201). There was no significant difference between the GG genotype and other genotypes in recurrent-free survival. The extrahepatic recurrence (EHR) rate of those with the GG genotype was significantly higher than that of those with the other genotypes (P = 0.036). The GG genotype was an independent risk factor for EHR (P = 0.008; HR 2.037).ConclusionsThe PD-1 SNP GG genotype is associated with poor survival and increased EHR in HCC. Furthermore, the GG genotype is an independent predictive factor for OS and EHR.